Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2021.03.017
- Author:
Yan LI
1
;
Zhen-Wei JIA
2
;
Xiao-Yang KONG
2
;
Gui-Rong CUI
2
;
Xiao-Yan LIU
2
Author Information
1. Department of Hematology, The First Hospital of Handan City, Handan 056002, Hebei Province, China,E-mmail: liyan19680404@163.com.
2. Department of Hematology, The First Hospital of Handan City, Handan 056002, Hebei Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse/genetics*;
MicroRNAs/genetics*;
Mutation;
Myeloid Differentiation Factor 88/genetics*;
Polymorphism, Genetic;
Prognosis
- From:
Journal of Experimental Hematology
2021;29(3):757-762
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between the polymorphism of miR-155 and its target gene MyD88 and clinicopathological features of diffuse large B-cell lymphoma (DLBCL).
METHODS:135 cases of DLBCL patients in our hospital from March 2015 to August 2017 were selected, and 90 cases of reactive hyperplasia of lymph nodes were selected as the control group. The relative expression of miR-155 and MyD88 gene polymorphism were detected in the two groups, and the relationship between miR-155 and MyD88 gene polymorphism and clinicopathological characteristics of DLBCL was analyzed.
RESULTS:The relative expression of miR-155 in DLBCL patients was significantly higher than that in the control group (P<0.05). The mutation rate of MyD88 L265P in DLBCL group was significantly higher than that in control group (P<0.05). The relative expression of miR-155 in patients with MyD88 L265P mutation was significantly higher than that in patients with wild-type DLBCL (P<0.05). The relative expression of miR-155 and the polymorphism of MyD88 L265P were associated with lesion location, stage, BCL-2 protein expression and MyD88 protein expression in DLBCL patients (t=7.461、8.804、6.487、10.812； χ
CONCLUSION:The abnormal expression of miR-155 and the mutation rate of MyD88 gene in DLBCL patients are increased, and the expression of miR-155 and the mutation of MyD88 gene affect the disease progression and prognosis of patients, which may be potential biological indicators for the diagnosis, treatment and prognosis of DLBCL.
